share_log

Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Addex Therapeutics | 6-K：外国发行人报告
美股SEC公告 ·  2024/07/15 18:14

Moomoo AI 已提取核心信息

Addex Therapeutics announced positive results from its GABAB positive allosteric modulator (PAM) chronic cough program, to be presented at the 13th London International Cough Symposium on July 19, 2024. In guinea pig models, the GABAB PAM candidate demonstrated significant dose-dependent reduction in citric acid-induced cough frequency, with improved safety margin compared to baclofen.The study revealed that the selective GABAB PAM showed minimal efficacious dose at 1 mg/kg, increased cough latency, and exhibited no tolerance after sub-chronic treatment. Notably, this marks the first demonstration of antitussive activity by a highly selective GABAB PAM in animal cough models, potentially offering advantages over baclofen, which is limited by side effects and short half-life.The research suggests potential for developing a best-in-class treatment for chronic cough, targeting an allosteric site of the GABAB receptor. This approach is expected to provide higher selectivity, better tolerability, and lack of tolerance compared to traditional orthosteric compounds like baclofen.
Addex Therapeutics announced positive results from its GABAB positive allosteric modulator (PAM) chronic cough program, to be presented at the 13th London International Cough Symposium on July 19, 2024. In guinea pig models, the GABAB PAM candidate demonstrated significant dose-dependent reduction in citric acid-induced cough frequency, with improved safety margin compared to baclofen.The study revealed that the selective GABAB PAM showed minimal efficacious dose at 1 mg/kg, increased cough latency, and exhibited no tolerance after sub-chronic treatment. Notably, this marks the first demonstration of antitussive activity by a highly selective GABAB PAM in animal cough models, potentially offering advantages over baclofen, which is limited by side effects and short half-life.The research suggests potential for developing a best-in-class treatment for chronic cough, targeting an allosteric site of the GABAB receptor. This approach is expected to provide higher selectivity, better tolerability, and lack of tolerance compared to traditional orthosteric compounds like baclofen.
Addex Therapeutics 宣布其 GABAb 正性别构调节剂（PAM）慢性咳嗽项目的积极结果，将于 2024 年 7 月 19 日在第 13 届伦敦国际咳嗽研讨会上发布。在豚鼠模型中，GABAb PAM 候选药物显示出明显的剂量依赖性减少柠檬酸引起的咳嗽频率，并且与巴克洛芬相比具有更好的安全边际。研究表明，选择性 GABAb PAM 在 1 mg/kg 的剂量下显示出最低的有效剂量，增加了咳嗽潜伏期，并且在亚慢性治疗后未出现耐受性。值得注意的是，这标志着高选择性 GABAb PAM 在动物咳嗽模型中首次展示了抗咳嗽活性，可能在优势于巴克洛芬方面，因为巴克洛芬受限于副作用和短半衰期。研究表明，针对 GABAb 受体的别构位点开发最佳治疗慢性咳嗽的潜力。这种方法预计将提供更高的选择性、更好的耐受性，以及与传统的正构化合物（如巴克洛芬）相比无耐受性。
Addex Therapeutics 宣布其 GABAb 正性别构调节剂（PAM）慢性咳嗽项目的积极结果，将于 2024 年 7 月 19 日在第 13 届伦敦国际咳嗽研讨会上发布。在豚鼠模型中，GABAb PAM 候选药物显示出明显的剂量依赖性减少柠檬酸引起的咳嗽频率，并且与巴克洛芬相比具有更好的安全边际。研究表明，选择性 GABAb PAM 在 1 mg/kg 的剂量下显示出最低的有效剂量，增加了咳嗽潜伏期，并且在亚慢性治疗后未出现耐受性。值得注意的是，这标志着高选择性 GABAb PAM 在动物咳嗽模型中首次展示了抗咳嗽活性，可能在优势于巴克洛芬方面，因为巴克洛芬受限于副作用和短半衰期。研究表明，针对 GABAb 受体的别构位点开发最佳治疗慢性咳嗽的潜力。这种方法预计将提供更高的选择性、更好的耐受性，以及与传统的正构化合物（如巴克洛芬）相比无耐受性。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Evaxion Biotech
    EVAX
    -- 6.030
    PMGC Holdings
    ELAB
    -- 3.100
    Lantern Pharma
    LTRN
    -- 5.400
    Transcode Therapeutics
    RNAZ
    -- 7.040
    Neuphoria Therapeutics
    NEUP
    -- 4.390
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。
    热门讨论
    科技巨头财报季拉开帷幕： 市场将如何反应？
    🎙️ 讨论： 1. 大型科技公司的财报能否再次引领各版块上涨？ 2. 科技巨头将会如何受到“特朗普因素”的影响？ 展开
    了解大科技股收益前需要知道的事项